Abstract: The invention features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain.
Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
Type:
Grant
Filed:
January 13, 2020
Date of Patent:
August 16, 2022
Assignee:
SIRNA THEREPEUTICS, INC.
Inventors:
Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
Abstract: Leave-on compositions to be applied to the skin, which after five minutes post-application provides an improved low residue level, where the composition includes an emulsifier having a particular HLB value and an emollient present in a weight amount that is equal to or greater than the weight amount of the emulsifier.
Type:
Grant
Filed:
March 6, 2018
Date of Patent:
August 2, 2022
Assignee:
Johnson & Johnson Consumer Inc.
Inventors:
Devin Garcia, Simarna Kaur, Janeta Nikolovski, Louis DeRidder
Abstract: A therapeutic treatment for preventing or reducing the formation of fibrosis comprising administering to a patient a UTX or JMJD3 inhibitor that are effective in preventing or reducing fibrosis in situations wherein access to an injury or dysmorphogenetic tissues before the fibrotic process becomes established in the tissues.
Type:
Grant
Filed:
September 25, 2017
Date of Patent:
August 2, 2022
Assignee:
THOMAS JEFFERSON UNIVERSITY
Inventors:
Janice L. Walker, Alexander Mazo, Svetlana Petruk, A. Sue Menko
Abstract: Compositions and methods for treating epilepsy and epileptic syndromes are described herein. The compositions and methods include therapeutically effective amounts of one or more dimebolins, or pharmaceutically acceptable salts thereof.
Abstract: Provided herein are, inter alia, methods and compositions for treating cancer in a subject in need thereof comprising a therapeutically effective amount of a stilbenoid compound and a progestin.
Abstract: The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.
Abstract: A formulation to be used for administering a therapeutically effective amount of an antimicrobiologically active monoglyceride to a mammal including administering a pharmaceutical composition having a total volume of 1-5000 ?L to a surface of the mammal such as the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface, the pharmaceutical composition including the therapeutically effective amount of the antimicrobiologically active monoglyceride dissolved or suspended in a volume of 1-5000 ?L of an methoxypolyethylene glycol referred to as mPEG and polyoxyethylene glycol (PEG)-fatty acid mono- or diglyceride so that upon administration of the pharmaceutical composition to the surface the formulation expresses thermostability within the range from below zero degrees C. to above 35-40° C. and thereby allows the antimicrobiologically active monoglyceride to exert its therapeutic effect.
Abstract: The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.
Abstract: A method of inhibiting neuroinflammation in neuron surrounding cells, includes a step of treating the neuron surrounding cells with at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof, to inhibit the neuroinflammation. A method of managing neuroinflammation or neuroinflammation mediated neurodegenerative disease or disorder in a subject in need thereof, includes administering at least one tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof to the subject. A composition includes at least one tyrosine kinase inhibitor or at least one sirtuin-2 inhibitor optionally along with pharmaceutically acceptable excipient.
Type:
Grant
Filed:
June 7, 2017
Date of Patent:
May 10, 2022
Assignee:
CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS
Inventors:
Taslimarif Saiyed, Ravi Manjithaya, Murumalla Ravi Kumar, Suresh Santhi Natesan, Janhavi Pandurangi, Aravinda K. Chavalmane, Shashank Rai
Abstract: The present disclosure provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, e.g. cancer, benign tumor, etc.). Related materials and methods are also provided herein.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
May 3, 2022
Assignee:
Indiana University Research and Technology Corporation
Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
Type:
Grant
Filed:
February 5, 2019
Date of Patent:
May 3, 2022
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Michael T. Nordsiek, Sharon F. Levy, James Hurn-Joung Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
Abstract: Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, said active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is comprised in the range 4.3 to 5.3.
Abstract: The invention relates to 2-octylcyclopropyl-1-carboxylic acid, in particular in the form of one of the isomers thereof in isolated form or in the form of a mixture of at least two of said isomers. The invention further relates to a method for synthesizing 2-octylcyclopropyl-1-carboxylic acid or at least one of the isomers thereof. Finally, the invention relates to the use of 2-octylcyclopropyl-1-carboxylic acid or of one of said isomers in isolated form or of one of the mixtures of at least two of the isomers thereof, as a perfuming agent. The invention further relates to the compositions including 2-octylcyclopropyl-1-carboxylic acid or one of said isomers in isolated form or one of the mixtures of at least two of the isomers thereof, as a perfuming agent.
Type:
Grant
Filed:
November 18, 2015
Date of Patent:
February 1, 2022
Assignees:
Albert Vielle, Centre National de la Recherche Scientifique (CNRS), Universite de Nice
Inventors:
Nicolas Baldovini, Céline Cerutti-Delasalle
Abstract: The invention disclosed herein relates to novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases. Particularly, the invention relates to potent and stable synergistic nutritional composition comprising combination of therapeutically active non-competitive amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPAR) antagonists and nuclear factor erythroid 2-related factor 2 (NRF2) activators, present in weight ratio of 1:0.001 to 1:0.5, along with pharmaceutically acceptable excipients. Further, the present synergistic nutritional composition is useful for treating conditions associated with seizure, fibrosis and diabetes.
Abstract: Disclosed herein is hyperbaric solution for injection of Ropivacaine Hydrochloride which comprises Ropivacaine Hydrochloride; a base/acid to adjust the pH and a baricity adjuster to modify Baricity of the injection solution.
Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
Abstract: The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
Type:
Grant
Filed:
August 12, 2016
Date of Patent:
December 28, 2021
Assignees:
The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Pharma Aktiengesellschaft
Inventors:
Luc De Waal, Matthew Meyerson, Heidi Greulich, Monica Schenone, Alex Burgin, Xiaoyun Wu, Ulrike Sack
Abstract: The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.
Type:
Grant
Filed:
July 15, 2019
Date of Patent:
December 14, 2021
Assignee:
Purdue Research Foundation
Inventors:
Mohamed Seleem, Mingji Dai, Dexter Cameron Davis, Haroon Taj Mohammad